Direct comparison of a novel antitachycardia pacing algorithm against present methods using virtual patient modeling.


Journal

Heart rhythm
ISSN: 1556-3871
Titre abrégé: Heart Rhythm
Pays: United States
ID NLM: 101200317

Informations de publication

Date de publication:
09 2020
Historique:
received: 05 11 2019
revised: 24 04 2020
accepted: 05 05 2020
pubmed: 22 5 2020
medline: 7 9 2021
entrez: 22 5 2020
Statut: ppublish

Résumé

Antitachycardia pacing (ATP) success rates as low as 50% for fast ventricular tachycardias (VTs) have been reported providing an opportunity for improved ATP to decrease shocks. The purpose of this study was to determine how a new automated antitachycardia pacing (AATP) therapy would perform compared with traditional burst ATP using computer modeling to conduct a virtual study. Virtual patient scenarios were constructed from magnetic resonance imaging and electrophysiological (EP) data. Cardiac EP simulation software (CARPEntry) was used to generate reentrant VT. Simulated VT exit sites were physician adjudicated against corresponding clinical 12-lead electrocardiograms. Burst ATP comprised 3 sequences of 8 pulses at 88% of VT cycle length, with each sequence decremented by 10 ms. AATP was limited to 3 sequences, with each sequence learning from the previous sequences. Two hundred fifty-nine unique ATP scenarios were generated from 7 unique scarred hearts. Burst ATP terminated 145 of 259 VTs (56%) and accelerated 2.0%. AATP terminated 189 of 259 VTs (73%) with the same acceleration rate. The 2 dominant ATP failure mechanisms were identified as (1) insufficient prematurity to close the excitable gap; and (2) failure to reach the critical isthmus of the VT. AATP reduced failures in these categories from 101 to 63 (44% reduction) without increasing acceleration. AATP successfully adapted ATP sequences to terminate VT episodes that burst ATP failed to terminate. AATP was successful with complex scar geometries and EP heterogeneity as seen in the real world.

Sections du résumé

BACKGROUND
Antitachycardia pacing (ATP) success rates as low as 50% for fast ventricular tachycardias (VTs) have been reported providing an opportunity for improved ATP to decrease shocks.
OBJECTIVE
The purpose of this study was to determine how a new automated antitachycardia pacing (AATP) therapy would perform compared with traditional burst ATP using computer modeling to conduct a virtual study.
METHODS
Virtual patient scenarios were constructed from magnetic resonance imaging and electrophysiological (EP) data. Cardiac EP simulation software (CARPEntry) was used to generate reentrant VT. Simulated VT exit sites were physician adjudicated against corresponding clinical 12-lead electrocardiograms. Burst ATP comprised 3 sequences of 8 pulses at 88% of VT cycle length, with each sequence decremented by 10 ms. AATP was limited to 3 sequences, with each sequence learning from the previous sequences.
RESULTS
Two hundred fifty-nine unique ATP scenarios were generated from 7 unique scarred hearts. Burst ATP terminated 145 of 259 VTs (56%) and accelerated 2.0%. AATP terminated 189 of 259 VTs (73%) with the same acceleration rate. The 2 dominant ATP failure mechanisms were identified as (1) insufficient prematurity to close the excitable gap; and (2) failure to reach the critical isthmus of the VT. AATP reduced failures in these categories from 101 to 63 (44% reduction) without increasing acceleration.
CONCLUSION
AATP successfully adapted ATP sequences to terminate VT episodes that burst ATP failed to terminate. AATP was successful with complex scar geometries and EP heterogeneity as seen in the real world.

Identifiants

pubmed: 32438017
pii: S1547-5271(20)30430-6
doi: 10.1016/j.hrthm.2020.05.009
pii:
doi:

Types de publication

Comparative Study Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

1602-1608

Subventions

Organisme : NHLBI NIH HHS
ID : R01 HL142913
Pays : United States

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Darrell J Swenson (DJ)

Medtronic plc, Minneapolis, Minnesota. Electronic address: darrell.swenson@gmail.com.

Robert T Taepke (RT)

Medtronic plc, Minneapolis, Minnesota.

Josh J E Blauer (JJE)

Medtronic plc, Minneapolis, Minnesota.

Eugene Kwan (E)

Department of Biomedical Engineering, University of Utah, Salt Lake City, Utah; Cardiovascular Medicine, University of Utah, Salt Lake City, Utah; Nora Eccles Harrison Cardiovascular Research and Training Institute, Salt Lake City, Utah.

Elyar Ghafoori (E)

Department of Biomedical Engineering, University of Utah, Salt Lake City, Utah; Cardiovascular Medicine, University of Utah, Salt Lake City, Utah.

Gernot Plank (G)

Gottfried Schatz Research Center-Biophysics, Medical University of Graz, Graz, Austria.

Edward Vigmond (E)

IHU Liryc, Electrophysiology and Heart Modeling Institute, Fondation Bordeaux Université, Bordeaux, France; University of Bordeaux, Bordeaux, France.

Rob S MacLeod (RS)

Department of Biomedical Engineering, University of Utah, Salt Lake City, Utah; Cardiovascular Medicine, University of Utah, Salt Lake City, Utah; Nora Eccles Harrison Cardiovascular Research and Training Institute, Salt Lake City, Utah.

Paul DeGroot (P)

Medtronic plc, Minneapolis, Minnesota.

Ravi Ranjan (R)

Cardiovascular Medicine, University of Utah, Salt Lake City, Utah; Nora Eccles Harrison Cardiovascular Research and Training Institute, Salt Lake City, Utah.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH